Revelation Biosciences (REVB) Cash from Operations (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Cash from Operations of 1966992.0 for Q4 2025, up 47.51% year-over-year from 1333428.58 in Q4 2024, and down 23.8% quarter-over-quarter from 1588901.0 in Q3 2025.
Revelation Biosciences (REVB) Cash from Operations (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Cash from Operations for 6 consecutive years, with 1966992.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 47.51% year-over-year to 1966992.0; the TTM figure through Dec 2025 stood at 8269581.0 (up 54.86% YoY), while the FY2025 annual figure was 8269581.0, up 54.86% from the prior year.
- Cash from Operations slipped to 1966992.0 in Q4 2025 per REVB's latest filing, from 1588901.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 947467.0 in Q4 2022 and bottomed at 9256984.0 in Q3 2024.
- Historically, Cash from Operations has averaged 2809355.6 across 5 years, with a median of 2308356.0 in 2021.
- Annual changes were most pronounced in 2021 — Cash from Operations sank 257349.31% — and 2025, when it soared 82.84%.
- Revelation Biosciences' Cash from Operations stood at 2878907.0 in 2021, then soared by 67.09% to 947467.0 in 2022, then plunged by 111.39% to 2002836.0 in 2023, then slumped by 87.12% to 3747641.0 in 2024, then soared by 47.51% to 1966992.0 in 2025.
- Business Quant data shows REVB's Cash from Operations at 1966992.0 in Q4 2025, 1588901.0 in Q3 2025, and 1919281.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.97 Mn |
| Dec 31, 2025 | -1.97 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -3.75 Mn |
| Dec 31, 2024 | -3.75 Mn |
| Sep 30, 2024 | -9.26 Mn |
| Sep 30, 2024 | -9.26 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -2.84 Mn |
| Mar 31, 2024 | -2.84 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Sep 30, 2023 | -1.72 Mn |